Adipocyte Plasma Membrane Associated Protein
Adipocyte plasma membrane associated proteins are a diverse group of molecules integral to the function and regulation of fat cells (adipocytes). These proteins reside on or within the plasma membrane of adipocytes, playing critical roles in nutrient uptake, hormone signaling, cell-to-cell communication, and maintaining cellular structure. Their proper function is essential for metabolic homeostasis and overall health.
Biological Basis
Section titled “Biological Basis”Many proteins associate with the plasma membrane through various mechanisms, including direct insertion, peripheral attachment, or lipid anchors. One specific mechanism involves glycosylphosphatidylinositol (GPI) anchors, which tether proteins to the outer leaflet of the cell membrane. The enzyme _GPLD1_(glycosylphosphatidylinositol specific phospholipase D1) is responsible for hydrolyzing the inositol phosphate linkage in these GPI-anchored proteins, thereby releasing them from the cell membrane into the extracellular space or circulation. This shedding process can modulate the availability of cell surface proteins, impacting their signaling and functional roles.
Clinical Relevance
Section titled “Clinical Relevance”Dysregulation of adipocyte plasma membrane associated proteins and their modifying enzymes can have significant clinical implications. For instance, _GPLD1_ has been implicated in metabolic health. Elevated serum levels of _GPLD1_ and increased _GPLD1_mRNA expression in the liver have been reported in individuals with nonalcoholic fatty liver disease (NAFLD) . While these sample sizes were substantial for discovery, robust replication in independent cohorts was crucial, with some follow-up studies expanding to include up to 20,623 participants.[1] Despite these efforts, some associations did not consistently meet stringent significance thresholds, suggesting that even larger samples are still needed to identify additional genetic variants and improve statistical power for gene discovery relevant to lipid metabolism and its associated proteins. [1] Moreover, certain SNP replications were equivocal, necessitating region-based association tests to confirm signals, which underscores the ongoing challenge of consistent and robust validation across diverse cohorts. [2]
The precision of reported genetic effect sizes can vary, with some analyses showing similar effect magnitudes but less significant P-values in specific subgroups, such as females, highlighting potential issues with statistical power or population-specific effects. [2] Furthermore, the reliance on genotype imputation, while essential for comprehensive genomic coverage, introduces an estimated error rate of 1.46% to 2.14% per allele. [3]Such imputation inaccuracies could subtly affect the accuracy of reported associations and, consequently, the interpretation of genetic influences on lipid metabolism and proteins like adipocyte plasma membrane associated protein.
Population Specificity and Phenotype Definition
Section titled “Population Specificity and Phenotype Definition”A significant limitation stems from the predominant focus of many studies on populations of European ancestry. [1] While some research included individuals from founder populations, which can facilitate gene discovery due to reduced genetic heterogeneity, their findings may not be directly generalizable to broader, more diverse populations. [2] The systematic exclusion of individuals of non-European ancestry from analyses [4] means that important genetic variations or differential genetic effects relevant to other ethnic groups might be overlooked. This limitation restricts the generalizability of findings to global populations and impacts a comprehensive understanding of how genetic variants influence lipid metabolism and related proteins across diverse human ancestries.
The definition and adjustment of lipid phenotypes also varied across studies. While most studies adjusted for common confounders such as age, sex, and age squared, some also included adjustments for BMI, diabetes status, use of oral contraceptives, pregnancy, or relatedness. [1] Inconsistent handling of lipid-lowering therapies (e.g., excluding users versus studies where information was unavailable) [1]could introduce variability or bias into the reported effect sizes. Moreover, the classification of some traits by dichotomization at clinical cut-offs or detectable limits, rather than continuous quantitative measures, might reduce statistical power and precision for identifying subtle genetic influences on metabolic processes, thereby affecting our understanding of proteins like adipocyte plasma membrane associated protein.[5]
Unaccounted Variability and Biological Complexity
Section titled “Unaccounted Variability and Biological Complexity”Despite identifying numerous genetic loci associated with lipid concentrations, the identified variants collectively explain only a small fraction of the total variability in these traits, with one study reporting only 6% of total variability explained. [2]This substantial “missing heritability” suggests that many other genetic factors, including rare variants, structural variations, or complex epistatic interactions, remain undiscovered. Furthermore, while some research incorporated environmental variables into multivariate models, the comprehensive interplay of gene-environment interactions and other non-genetic confounders is not fully elucidated, representing a significant gap in understanding the complete etiology of lipid metabolism and its impact on proteins like adipocyte plasma membrane associated protein.[2]
The studies primarily identify association signals, often through proxy SNPs that are in linkage disequilibrium with the true causal variants. [2]Distinguishing these proxy SNPs from the actual functional variants requires further fine-mapping and in-depth functional validation, which remains a fundamental challenge in GWAS. While some associations show strong statistical support for a gene and its protein product, the ultimate validation of these findings necessitates replication in other cohorts and comprehensive functional studies to elucidate the precise biological mechanisms by which these genetic variants influence lipid metabolism and, consequently, the function of proteins like adipocyte plasma membrane associated protein.[6] This highlights the ongoing need to move beyond statistical association to a mechanistic understanding.
Variants
Section titled “Variants”Genetic variations play a crucial role in influencing metabolic pathways and cellular functions, including those within adipocytes, which are central to lipid metabolism and energy storage. Genome-wide association studies (GWAS) have been instrumental in identifying numerous loci associated with lipid levels and related metabolic traits, providing insights into the complex genetic architecture underlying these processes. [3] Among these, variants impacting genes involved in fatty acid synthesis and regulation of adipocyte function are of particular interest.
The variant rs73095987 is associated with the ACSS1 gene, which encodes Acyl-CoA Synthetase Short-Chain Family Member 1. ACSS1is an enzyme critical for converting acetate into acetyl-CoA, a fundamental precursor in various metabolic pathways, including the synthesis of fatty acids, cholesterol, and energy production within mitochondria.[7] In adipocytes, ACSS1 activity can significantly impact lipid droplet formation and overall cellular lipid homeostasis. A variant like rs73095987 could potentially influence ACSS1gene expression or the efficiency of the enzyme, thereby altering the availability of acetyl-CoA for lipid synthesis and breakdown. Such alterations can have implications for the function of adipocyte plasma membrane associated protein (APMAP), which itself is involved in adipocyte differentiation and lipid metabolism, suggesting a potential interplay in maintaining metabolic balance. [1]
Another variant, rs8125909 , is linked to both the APMAP and ACSS1 genes, suggesting it may reside in a regulatory region influencing both, or its effects are mediated through a pathway involving both proteins. APMAP(Adipocyte Plasma Membrane Associated Protein) is known to play a direct role in adipocyte differentiation and lipid metabolism, making it a key player in fat cell function and the maintenance of healthy adipose tissue.[2] The influence of rs8125909 on APMAP could affect the structural and functional integrity of the adipocyte plasma membrane, impacting nutrient uptake and signaling. Simultaneously, its potential effect on ACSS1 could modulate the intracellular lipid synthesis machinery, creating a combined effect on adipocyte health and susceptibility to metabolic disorders. [8]
The variant rs73112274 is associated with LINC02967 and CST7. LINC02967is a long intergenic non-coding RNA (lncRNA), a class of RNA molecules known for their diverse roles in regulating gene expression, including processes related to metabolism, cell differentiation, and disease progression. Its modulation byrs73112274 could lead to altered expression of target genes, potentially influencing adipocyte biology or related metabolic pathways. CST7(Cystatin F) encodes a cysteine protease inhibitor, and while not directly involved in lipid metabolism, proteases and their inhibitors are crucial for protein turnover, extracellular matrix remodeling, and inflammatory responses—all processes that can indirectly affect the development and function of adipose tissue.[6] Therefore, rs73112274 may contribute to the complex regulation of adipocyte function through its impact on gene expression and cellular proteolytic balance, highlighting the intricate genetic landscape underlying metabolic traits. [9]
Key Variants
Section titled “Key Variants”Biological Background
Section titled “Biological Background”Lipid Transport and Cellular Uptake
Section titled “Lipid Transport and Cellular Uptake”The regulation of lipid concentrations in the bloodstream is a complex process involving the synthesis, transport, and cellular uptake of various lipid molecules, including triglycerides and cholesterol. These lipids are encapsulated within lipoprotein particles, which circulate throughout the body and interact with cell membranes to deliver or retrieve their lipid cargo. Key apolipoproteins, such asAPOE, APOB, APOC1, APOC2, APOC3, and APOC4, are crucial structural components of these lipoproteins, helping to stabilize and solubilize them in the blood and facilitating their recognition by cellular receptors. [10] For instance, APOE plays a significant role in cholesterol transport, while APOA5notably influences triglyceride levels. The interaction of these lipoproteins with specific receptors on the plasma membrane of cells, including adipocytes, is essential for lipid delivery and storage.
Cellular mechanisms for lipid handling involve transporters and receptors embedded within the plasma membrane. For example, the lipoprotein receptorLDLR is vital for the uptake of cholesterol-rich lipoproteins into cells. [3] Another protein, SORT1, has been identified as a possible endocytic receptor for lipoprotein lipase (LPL), impacting its activity and the subsequent processing of triglycerides. [3] Furthermore, the ABCA1 transporter is critical for the efflux of cholesterol from cells, contributing to HDL formation, highlighting the dynamic interplay between intracellular lipid metabolism and membrane-associated transport processes. [3] These membrane-bound components are central to how cells, particularly adipocytes, manage lipid acquisition and release, thereby maintaining systemic lipid balance.
Enzymatic Regulation of Lipid Metabolism
Section titled “Enzymatic Regulation of Lipid Metabolism”A network of enzymes intricately controls the synthesis, modification, and breakdown of lipids throughout the body. Lipoprotein lipase (LPL) is a pivotal enzyme responsible for the hydrolysis of triglycerides found in circulating lipoproteins, releasing fatty acids that can then be absorbed by peripheral tissues, including adipose tissue. [10] Other lipases, such as hepatic lipase (LIPC) and endothelial lipase (LIPG), also contribute to the metabolism of various lipoproteins, affecting their composition and clearance. [3] The activity of these lipases can be modulated by inhibitors like ANGPTL3, which plays a role in regulating triglyceride levels by restraining lipase function.[3]Beyond triglyceride metabolism, enzymes likeMVK are involved in the cholesterol biosynthesis pathway, and CETPmediates the transfer of cholesterol esters between different lipoprotein particles, further influencing overall lipid profiles.[3] Additionally, the BCMO1 enzyme is responsible for the conversion of beta-carotene to retinal, demonstrating the diverse enzymatic roles in nutrient processing and metabolism. [11]
Genetic Influences on Lipid Homeostasis
Section titled “Genetic Influences on Lipid Homeostasis”Genetic mechanisms play a substantial role in determining an individual’s lipid profile and susceptibility to related metabolic disorders. Numerous genes encode critical proteins involved in the entire cycle of lipoprotein formation, activity, and turnover. For instance, common genetic variations in genes likeLPL and the APOE-C1-C2-C4 gene cluster are strongly associated with circulating levels of HDL and triglycerides. [10] Polymorphisms within LPL and APOEhave been specifically linked to increases in LDL cholesterol and decreases in HDL cholesterol, highlighting their significant impact on cardiovascular health.[10] Beyond structural and enzymatic components, transcription factors like MLXIPLregulate lipid synthesis by activating triglyceride production, demonstrating a genetic influence on metabolic processes at the transcriptional level.[3] The cumulative effect of these genetic variations, including those affecting potential receptor-modifying glycosyltransferases such as B4GALT4, B3GALT4, and GALNT2, contributes to the inter-individual variability in lipid concentrations and disease risk.[3]
Systemic Lipid Balance and Health Implications
Section titled “Systemic Lipid Balance and Health Implications”Maintaining proper lipid homeostasis is crucial for overall health, and disruptions in these processes can lead to significant pathophysiological consequences. Imbalances in circulating lipid concentrations, particularly elevated triglycerides and LDL cholesterol or reduced HDL cholesterol, are major risk factors for coronary artery disease.[10] The genes that influence lipid levels exert their effects at a systemic level, impacting the function of various organs and tissues involved in lipid metabolism, such as the liver, adipose tissue, and vascular endothelium. For instance, the efficient breakdown of triglycerides by LPL and the proper transport of cholesterol by apolipoproteins like APOE are essential for preventing the accumulation of harmful lipid species. [10]Understanding the intricate genetic and molecular underpinnings of lipid metabolism is therefore vital for elucidating disease mechanisms, identifying individuals at risk, and developing targeted interventions to restore homeostatic balance and mitigate cardiovascular morbidity.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Adipocyte Plasma Membrane in Lipid Dynamics and Metabolism
Section titled “Adipocyte Plasma Membrane in Lipid Dynamics and Metabolism”The plasma membrane of adipocytes serves as a crucial interface for the intricate regulation of lipid metabolism, encompassing both the synthesis and breakdown of various lipid species. Proteins embedded within or associated with this membrane play pivotal roles in processing triglycerides and cholesterol, which are fundamental for energy storage and cellular structure. For instance, Angiopoietin-like protein 4 (Angptl4) acts as a potent inhibitor of lipoprotein lipase (LPL), thereby influencing the catabolism of circulating triglycerides and contributing to hyperlipidemia. [12] Similarly, apolipoproteins like Apo CIII, often found on the surface of very low-density lipoprotein (VLDL) particles, can diminish VLDL fractional catabolic rates, leading to elevated triglyceride levels.[13] The phospholipid transfer protein (PLTP) also impacts high-density lipoprotein (HDL) levels, demonstrating the complex interplay of membrane-associated proteins in maintaining systemic lipid balance. [14]
Beyond circulating lipids, adipocyte plasma membrane proteins are integral to cellular lipid biosynthesis and uptake. The FADS1 and FADS2 gene cluster, for example, encodes desaturases that are critical for the synthesis of polyunsaturated fatty acids, which in turn dictate the composition of membrane phospholipids and cellular signaling molecules. [15] Furthermore, the Niemann-Pick C1-like 1 (NPC1L1) protein, located on the plasma membrane, is directly involved in the absorption of cholesterol, highlighting its role in regulating cellular and systemic cholesterol homeostasis. [4] These mechanisms collectively underscore how adipocyte plasma membrane components orchestrate lipid flux, from uptake and synthesis to secretion and breakdown, thereby impacting overall metabolic health.
Signal Transduction and Receptor-Mediated Processes
Section titled “Signal Transduction and Receptor-Mediated Processes”Adipocyte plasma membrane associated proteins are central to receiving and transducing extracellular signals, initiating intracellular cascades that regulate adipocyte function. Specialized receptors on the membrane detect various ligands, leading to conformational changes and the activation of downstream signaling pathways. For example, low-density lipoprotein receptor-related protein (LRP) interacts with transcription factors like MafB, suggesting a role in linking extracellular lipid sensing to gene expression programs within the adipocyte. [16] Another key player, Pleckstrin, associates with plasma membranes and can induce the formation of membrane projections, a process requiring its phosphorylation and NH2-terminal PH domain, indicating its involvement in cytoskeletal rearrangements and signal propagation. [17]
Nuclear receptors, while not strictly plasma membrane proteins, often interact with membrane-derived signals or ligands that traverse the membrane. Liver X receptor alpha (NR1H3 or LXRA), for instance, acts as an orphan nuclear receptor that mediates lipid-inducible gene expression, directly influencing metabolic pathways in response to lipid availability. [4] The leptin receptor (LEPR) on adipocytes is also critical for sensing circulating leptin, a hormone that regulates energy balance and satiety, further demonstrating how membrane-associated signaling pathways integrate systemic metabolic cues.[8] These intricate signaling networks ensure that adipocytes respond appropriately to nutrient status and hormonal signals, maintaining metabolic equilibrium.
Transcriptional and Post-Translational Regulatory Mechanisms
Section titled “Transcriptional and Post-Translational Regulatory Mechanisms”The activity and abundance of adipocyte plasma membrane associated proteins are tightly controlled through a combination of gene regulation and post-translational modifications, ensuring dynamic adaptation to physiological needs. Transcriptional regulators, such as those encoded by the CTCF-PRMT8gene, may be involved in hormone-dependent gene silencing, directly impacting the expression of metabolic genes in adipocytes.[4] Furthermore, alternative splicing mechanisms are crucial for generating protein diversity and regulating protein function or localization. For example, alternative splicing of HMG-CoA reductase (HMGCR) exon 13 has been shown to affect its function, and alternative splicing of APOB mRNA can generate novel isoforms with distinct properties. [18]
Post-translational modifications, such as phosphorylation, are also vital regulatory mechanisms. The requirement for phosphorylation of Pleckstrin to associate with plasma membranes and induce projections illustrates how dynamic modifications can control protein localization and activity. [17] Additionally, the oligomerization state of HMGCR influences its degradation rate, providing a feedback loop to control cholesterol synthesis. [19]Allosteric control, exemplified by the regulation of glucokinase by a fructose-1-phosphate-sensitive protein, represents another layer of rapid enzymatic regulation critical for glucose metabolism within adipocytes.[20]
Integrated Metabolic and Inflammatory Crosstalk
Section titled “Integrated Metabolic and Inflammatory Crosstalk”Adipocyte plasma membrane associated proteins operate within a highly integrated biological network, characterized by extensive crosstalk between metabolic and inflammatory pathways, which collectively contribute to systemic homeostasis. For instance, genetic variations in glucokinase regulatory protein (GCKR) are associated with both elevated fasting serum triacylglycerol levels and altered insulin sensitivity, highlighting its role in linking glucose and lipid metabolism.[21] Similarly, loci associated with metabolic syndrome pathways, including LEPR, HNF1A, IL6R, and GCKR, have been found to associate with plasma C-reactive protein (CRP) levels, demonstrating a direct link between metabolic health and inflammatory markers. [8]
This intricate pathway crosstalk is further exemplified by the impact of APOE genetic variation, which affects not only plasma LDL-cholesterol and apoE protein levels but also circulating C-reactive protein, underscoring its multifaceted role in both lipid transport and inflammatory responses. [8] The interaction between variants in PPARG and interleukin-6 (IL-6) genes also contributes to obesity-related metabolic risk factors, illustrating how genetic predispositions can modulate the integration of inflammatory and metabolic signals.[22] These network interactions and hierarchical regulations ensure a coordinated cellular response, but their dysregulation can lead to complex metabolic diseases.
Dysregulation in Metabolic Disease
Section titled “Dysregulation in Metabolic Disease”Dysregulation of adipocyte plasma membrane associated proteins and their pathways forms a cornerstone of various metabolic diseases, including dyslipidemia, obesity, and type 2 diabetes. Common genetic variants at numerous loci contribute to polygenic dyslipidemia, often by affecting the function or expression of proteins involved in lipid transport and metabolism.[1] For instance, the inhibition of LPL by Angptl4 or the reduced catabolism of VLDL due to Apo CIIIcan lead to severe hypertriglyceridemia, a key feature of metabolic syndrome and a risk factor for cardiovascular disease.[12]
Furthermore, genetic predispositions to obesity, such as common variants in theFTO gene and near MC4R, indicate how plasma membrane associated pathways indirectly contribute to the regulation of fat mass and body weight.[23]In the context of glucose homeostasis, variations within theG6PC2gene are associated with fasting plasma glucose levels, pointing to the involvement of adipocyte-related glucose metabolism in the etiology of type 2 diabetes.[24]Understanding these disease-relevant mechanisms is critical for identifying potential therapeutic targets, such as dietary fish oils used to reduce plasma lipids in hypertriglyceridemia, offering strategies to counteract pathway dysregulation and improve metabolic health.[25]
References
Section titled “References”[1] Kathiresan S, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet., vol. 40, 2008, pp. 189-197.
[2] Sabatti, C., et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nature Genetics, vol. 41, no. 1, 2009, pp. 35-46.
[3] Willer, C. J., et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nature Genetics, vol. 40, no. 2, 2008, pp. 161-69.
[4] Aulchenko YS, et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nat Genet., vol. 40, 2008, pp. 191-197.
[5] Melzer, D., et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genetics, vol. 4, no. 5, 2008, e1000072.
[6] Benjamin, E. J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Medical Genetics, vol. 8, 2007, p. 58.
[7] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet., vol. 4, no. 11, 2008, e1000282.
[8] Ridker PM, et al. “Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study.”Am J Hum Genet., vol. 82, no. 5, 2008, pp. 1141-1152.
[9] Aulchenko, Y. S., et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nature Genetics, vol. 41, no. 1, 2009, pp. 47-55.
[10] Middelberg, R.P., et al. “Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits.”BMC Med Genet, vol. 12, no. 1, 2011, pp. 121.
[11] Ferrucci, L., et al. “Common variation in the beta-carotene 15,15’-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study.” Am J Hum Genet, vol. 84, no. 2, 2009, pp. 19185284.
[12] Yoshida K, Shimizugawa T, Ono M, Furukawa H. “Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.”J. Lipid Res., vol. 43, 2002, pp. 1770–1772.
[13] Aalto-Setala K, et al. “Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.”J. Clin. Invest., vol. 90, 1992, pp. 1889–1900.
[14] Jiang XC, et al. “Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels.”J. Clin. Invest., vol. 103, 1999, pp. 907–914.
[15] Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet., vol. 15, 2006, pp. 1745–1756.
[16] Petersen HH, et al. “Low-density lipoprotein receptor-related protein interacts with MafB, a regulator of hindbrain development.”FEBS Lett., vol. 565, 2004, pp. 23–27.
[17] Ma AD, Brass LF, Abrams CS. “Pleckstrin associates with plasma membranes and induces the formation of membrane projections: requirements for phosphorylation and the NH2-terminal PH domain.” J Cell Biol., vol. 136, 1997, pp. 1071–1079.
[18] Burkhardt R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol., vol. 28, no. 12, 2008, pp. 2090-2096.
[19] Cheng HH, Xu L, Kumagai H, Simoni RD. “Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase.” J Biol Chem., vol. 274, 1999, pp. 17171–17178.
[20] Malaisse WJ, Malaisse-Lagae F, Davies DR, Vandercammen A, Van Schaftingen E. “Regulation of glucokinase by a fructose-1-phosphate-sensitive protein in pancreatic islets.”Eur. J. Biochem., vol. 190, 1990, pp. 539–545.
[21] Saxena R, et al. “Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.”Science., vol. 316, 2007, pp. 1331-1336.
[22] Barbieri M, Rizzo MR, Papa M, Acampora R, De Angelis L, Olivieri F, Marchegiani F, Franceschi C, Paolisso G. “Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors.”Exp Gerontol., vol. 40, 2005, pp. 599-604.
[23] Frayling TM, et al. “A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.”Science., vol. 316, 2007, pp. 889–894.
[24] Bouatia-Naji N, et al. “A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels.”Science., vol. 316, 2008, pp. 1037-1041.
[25] Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR. “Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia.” N. Engl. J. Med., vol. 312, 1985, pp. 1210–1216.